Search
+
    Invest with Confidence. Lead with Insights.
    • Drench in the knowledge with exclusive insights, ePaper & smart market tools with ETPrime.

    Can Sun Pharma's quarterly show reinforce investor confidence in stock?

    Synopsis

    The company intends to increase its specialty drug portfolio in its core areas of dermatology and ophthalmology. This comes at a time when the company’s generic business continues to face pricing pressure. The company’s Halol plant, receiving an import alert from the USFDA earlier in December, remains a challenge for Sun.

    ET Intelligence Group: Having hit a 52-week high Monday, the Sun Pharma stock closed 1.6% lower after the company announced its December quarter earnings Tuesday.The performance has been in line with the Street’s expectations, with consolidated revenues expanding at 13% and net profit at 5%. The ebitda margin rose marginally by 30 bps to 26.7%. The company also declared an interim dividend of Rs 7.5 per share.However, all this failed to impress
    • FONT SIZE
    • SAVE
    • PRINT
    • COMMENT
    ET

    Uh-oh! This is an exclusive story available for selected readers only.

    Worry not. You’re just a step away.

    Why ?

    • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

    • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

    • Clean experience with
      Minimal Ads
    • Comment & Engage with ET Prime community
    • Exclusive invites to Virtual Events with Industry Leaders
    • A trusted team of Journalists & Analysts who can best filter signal from noise
    • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

    The Economic Times